OpGen Accounts Receivables 2011-2026 | OPGN

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables OpGen

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
29.3 K	103 K	514 K	1.17 M	653 K	568 K	374 K	810 K	542 K	679 K	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.17 M	29.3 K	544 K

Quarterly Accounts Receivables OpGen

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
4.04 M	4.04 M	34.1 K	29.3 K	24.4 K	25.4 K	-	103 K	423 K	620 K	667 K	514 K	665 K	738 K	266 K	1.17 M	751 K	473 K	486 K	653 K	653 K	653 K	653 K	568 K	568 K	568 K	568 K	374 K	374 K	374 K	374 K	810 K	810 K	810 K	810 K	542 K	542 K	542 K	542 K	679 K	679 K	679 K	679 K	504 K	504 K	504 K	504 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
4.04 M	24.4 K	687 K

Accounts Receivables of other stocks in the Diagnostics research industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Akumin AKU	114 M	-	-17.87 %	$ 25.9 M	Canada
Bioventus BVS	128 M	$ 8.93	0.62 %	$ 595 M	USA
Aspira Women's Health AWH	1.24 M	-	-6.19 %	$ 10.5 M	USA
Castle Biosciences CSTL	51.2 M	$ 26.01	0.68 %	$ 722 M	USA
DexCom DXCM	1.22 B	$ 68.14	2.71 %	$ 26.6 B	USA
Charles River Laboratories International CRL	709 M	$ 153.97	1.32 %	$ 7.63 B	USA
CareDx, Inc CDNA	42.6 M	$ 17.49	0.98 %	$ 932 M	USA
Guardant Health GH	138 M	$ 87.81	0.72 %	$ 11 B	USA
Accelerate Diagnostics AXDX	2.42 M	-	-61.36 %	$ 2.46 M	USA
Exact Sciences Corporation EXAS	299 M	$ 103.91	0.06 %	$ 19.6 B	USA
Global Cord Blood Corporation CO	416 M	-	-	$ 399 M	China
Fulgent Genetics FLGT	69 M	$ 15.53	3.88 %	$ 470 M	USA
Biodesix BDSX	8.6 M	$ 16.43	-4.97 %	$ 2.13 B	USA
ICON Public Limited Company ICLR	1.34 B	$ 99.67	2.11 %	$ 8.22 B	Irlanda
Anixa Biosciences ANIX	173 K	$ 2.87	1.06 %	$ 93.1 K	USA
IQVIA Holdings IQV	3.4 B	$ 167.94	1.91 %	$ 28.9 B	USA
Danaher Corporation DHR	3.91 B	$ 195.04	1.91 %	$ 139 B	USA
Biocept BIOC	2.15 M	-	-13.05 %	$ 7.29 M	USA
Heska Corporation HSKA	29.5 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	1.42 M	-	-20.0 %	$ 1.06 M	USA
Illumina ILMN	735 M	$ 121.88	2.18 %	$ 19.4 B	USA
Quest Diagnostics Incorporated DGX	1.41 B	$ 198.1	-0.43 %	$ 22 B	USA
QIAGEN N.V. QGEN	381 M	-	-	$ 10.6 B	Niderland
Agilent Technologies A	1.17 B	$ 113.81	1.77 %	$ 34.6 B	USA
BioNano Genomics BNGO	4.75 M	$ 1.13	1.69 %	$ 1.44 M	USA
DarioHealth Corp. DRIO	3.16 M	$ 9.28	10.24 %	$ 263 M	Israel
NeoGenomics NEO	159 M	$ 8.3	0.67 %	$ 1.06 B	USA
Neogen Corporation NEOG	153 M	$ 9.2	0.93 %	$ 2 B	USA
Lantheus Holdings LNTH	359 M	$ 78.55	0.06 %	$ 5.3 B	USA
Chembio Diagnostics CEMI	6.54 M	-	0.22 %	$ 16.8 M	USA
Pacific Biosciences of California PACB	35.4 M	$ 1.41	3.68 %	$ 423 M	USA
Co-Diagnostics CODX	304 K	$ 4.4	101.83 %	$ 129 M	USA
Medpace Holdings MEDP	402 M	$ 453.81	0.04 %	$ 13.1 B	USA
Motus GI Holdings MOTS	76 K	-	-34.28 %	$ 263 K	Israel
Mettler-Toledo International MTD	778 M	$ 1 213.99	1.24 %	$ 25 B	Schweiz
DermTech DMTK	2.58 M	-	-11.32 %	$ 2.94 M	USA
National Research Corporation NRC	11.1 M	$ 17.53	0.75 %	$ 392 M	USA
Invitae Corporation NVTA	96.1 M	-	-	$ 21.2 M	USA
Enzo Biochem ENZ	3.99 M	-	-8.98 %	$ 14.8 K	USA
Natera NTRA	244 M	$ 199.0	0.67 %	$ 19.6 B	USA
OPKO Health OPK	118 M	$ 1.2	0.42 %	$ 833 M	USA